EuroBiotech: More Articles of Note


> Genmab outlined plans to increase its spending by as much as 45% in 2020. The anticipated surge in operating expenses reflects Genmab’s plans for development of its CD3xCD20 and PD-L1x4-1BB bispecifics. Annual report

> Montis Biosciences raised €8.4 million ($9.1 million) to advance immuno-oncology treatments for solid tumors. Pfizer Ventures was among the organizations to invest in the round. Statement 

> Mereo BioPharma received a $3 million equity investment. The U.S. investor bought the stock at a 20% discount to Mereo’s closing price the day before the deal was disclosed. Release 

> DuPont Nutrition & Biosciences entered into a collaboration with MRM Health. The collaborators will combine DuPont’s strains with MRM’s technology to create microbiome-based therapeutics. Statement 

> A Parkinson’s disease collaboration between Servier and Oncodesign passed its first milestone. The event triggered a €1 million milestone payment from Servier. Release 

> The U.K. government made Pfizer’s old Sandwich campus one of six Life Science Opportunity Zones. Government officials will work with the zones to attract investment. Statement 

Suggested Articles

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.